Published: June 5, 2017
Boston—Serum microRNA signatures have the potential to identify patients with non-alcoholic steatohepatitis who need treatment for the condition, researchers have found.
The discovery, if confirmed, would be welcome news given that rates of NASH have been climbing alongside rising rates of obesity. Distinguishing NASH from simple steatosis is important because NASH can progress to end-stage liver disease. Liver biopsy is the gold standard for diagnosing NASH, but it is expensive, has risks…